Clinical trials: Blood Protein Disorders
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth…
- Trial name
- NCT00546377
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.
- Trial name
- NCT01355705
- Testing
- Amrubicin, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michaela Liedtke
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (allotransplant) has been used to treat many kinds of cancer that develop in cells from the blood or immune system.
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemias, Multiple Myeloma With Plasmacytoma
- Trial name
- NCT00984165
- Testing
- Single fraction radiation, Donor Lymphocyte Infusion (DLI), Apheresis
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT01556438
- Testing
- Tabalumab, Bortezomib IV, Bortezomib SC
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days Bendamustine: once…
- Trial name
- NCT01754402
- Testing
- Bendamustine, Pomalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Cristina Gasparetto
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00589563
- Testing
- anti-thymocyte globulin, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Reduced Intensity Double Umbilical Cord Blood Transplantation
This trial will use two cord blood units for transplantation using a reduced intensity regimen rather than using intense doses of chemotherapy and radiation therapy.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01408563
- Testing
- Fludarabine, Melphalan, Total Body Radiation
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Hemophilia
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
This study will examine viral dynamic responses in subjects with chronic hepatitis C and hemophilia when treated with pegylated interferon + ribavirin and telaprevir.
- Trial name
- HCV/Hemophil (NCT01704521)
- Testing
- PegInterferon, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Kenneth Sherman
Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)
- Trial name
- ELOQUENT - 1 (NCT01335399)
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
- Where
- 235 sites in United States, Australia and 18 more
- Volunteers
- 748 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2, Renal Insufficiency
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have reduced kidney function.
- Trial name
- NCT01064414
- Testing
- Canagliflozin
- Where
- 106 sites in United States, Australia and 16 more
- Volunteers
- 272 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Severe Hemophilia A
Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A
This study will determine the efficacy of human-cl rhFVIII in previously treated patients with severe hemophilia A during prophylactic treatment, treatment of bleeding episodes and in surgical prophylaxis.
- Trial name
- NCT01125813
- Testing
- recombinant Factor VIII
- Where
- 11 sites in Austria, Bulgaria and 2 more
- Volunteers
- 32 people
- Sponsor
- Octapharma
Hemophilia
Patient Reported Outcomes Burdens and Experiences - Phase 2
The Patient Reported Outcomes, Burdens, and Experiences (PROBE) Study aims to develop a new global tool to enhance the direct patient-voice in health care decision-making.
- Trial name
- PROBE (NCT02439710)
- Testing
- Quality of life measure (survey)
- Where
- Canada
- Volunteers
- 656 people
- Sponsor
- McMaster University
Multiple Myeloma, Myeloma
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Background: Recent studies have shown that smoldering multiple myeloma has a high risk of progressing to multiple myeloma, an aggressive type of bone marrow cancer, within 5 years of diagnosis.
- Conditions
- Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT01248455
- Testing
- (Anti-KIR)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/refractory Multiple Myeloma (MM) is an incurable disorder with a poor prognosis. Carfilzomib is a novel proteasome inhibitor with activity in this setting.
- Trial name
- NCT01496118
- Testing
- panobinostat, carfilzomib
- Where
- 13 sites in United States
- Volunteers
- 80 people
- Sponsor
- SCRI Development Innovations, LLC
Hypofibrinogenemia, Bleeding
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients.
- Trial name
- NCT05711524
- Testing
- Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Hemophilia A
Survey of Inhibitors in Plasma-Product Exposed Toddlers
The primary objective of the study is to assess the immunogenicity of VWF/FVIII and of rFVIII concentrates by determining the frequency of inhibitor development in previously untreated patients (PUPs) or minimally blood…
- Trial name
- SIPPET (NCT01064284)
- Testing
- PLASMA DERIVED Factor VIII, Recombinant FVIII
- Where
- 48 sites in United States, Argentina and 12 more
- Volunteers
- 303 people
- Sponsor
- Fondazione Angelo Bianchi Bonomi
Multiple Myeloma
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side…
- Trial name
- NCT00843310
- Testing
- Lenalidomide (Revlimid), Melphalan, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.